NASDAQ : BBOT
BridgeBio Oncology Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 2.7 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 216.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Selling, General & Admin | 36.80M | 24.62M | 7.76M | 8.48M |
| Research & Development | 162.15M | 121.20M | 73.11M | 56.29M |
| Operating Expenses | 198.96M | 145.82M | 80.86M | 64.77M |
| Operating Income | -198.96M | -145.82M | -80.86M | -64.77M |
| Interest & Investment Income | 15.36M | 11.34M | 6.38M | 72.00K |
| Other Non Operating Income (Expenses) | 1.48M | 432.00K | 211.00K | |
| Pretax Income | -182.11M | -134.04M | -74.28M | -64.70M |
| Net Income | -182.11M | -134.04M | -74.28M | -64.70M |
| Net Income to Common | -182.11M | -134.04M | -74.28M | -64.70M |
| Shares Outstanding (Basic) | 71.16M | 31.14M | 12.90K | 124.73K |
| Shares Outstanding (Diluted) | 71.16M | 31.14M | 12.90K | 124.73K |
| EPS (Basic) | -2.56 | -4.30 | -5,756.41 | -518.73 |
| EPS (Diluted) | -2.56 | -4.30 | -5,756.41 | -518.73 |
| Free Cash Flow | -151.56M | -114.50M | -55.08M | -52.49M |
| Free Cash Flow Per Share | -2.13 | -3.68 | -4,268.47 | -420.87 |
| EBITDA | -198.65M | -145.54M | -80.66M | -64.68M |
| D&A For EBITDA | 307.00K | 280.00K | 208.00K | 92.00K |
| EBIT | -198.96M | -145.82M | -80.86M | -64.77M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Cash & Equivalents | 54.06M | 373.69M | 30.85M | 250.00K |
| Short-Term Investments | 171.65M | 51.77M | 124.78M | |
| Cash & Short-Term Investments | 225.71M | 425.46M | 155.63M | 250.00K |
| Other Receivables | 661.00K | 386.00K | 81.00K | 1.72M |
| Receivables | 661.00K | 386.00K | 81.00K | 1.72M |
| Prepaid Expenses | 16.01M | 6.55M | 2.98M | 1.96M |
| Total Current Assets | 242.38M | 432.40M | 158.69M | 3.94M |
| Property, Plant & Equipment | 2.98M | 3.29M | 490.00K | 596.00K |
| Other Long-Term Assets | 12.93M | 12.70M | 5.12M | 1.41M |
| Total Assets | 376.71M | 448.38M | 164.30M | 5.94M |
| Accounts Payable | 6.73M | 1.37M | 3.07M | 575.00K |
| Accrued Expenses | 43.37M | 32.61M | 12.92M | 3.54M |
| Current Portion of Leases | 554.00K | 522.00K | ||
| Other Current Liabilities | 986.00K | 534.00K | 3.59M | 12.66M |
| Total Current Liabilities | 51.63M | 35.04M | 19.58M | 16.77M |
| Long-Term Leases | 1.96M | 2.24M | ||
| Total Liabilities | 53.59M | 37.28M | 19.58M | 16.77M |
| Common Stock | 8.00K | 8.00K | ||
| Additional Paid-In Capital | 779.19M | 767.64M | 43.54M | 32.61M |
| Retained Earnings | -455.13M | -356.57M | -222.52M | -148.25M |
| Comprehensive Income & Other | -959.00K | 16.00K | 348.00K | |
| Total Common Equity | 323.11M | 411.10M | -178.64M | -115.64M |
| Shareholders' Equity | 323.11M | 411.10M | 144.72M | -10.83M |
| Total Liabilities & Equity | 376.71M | 448.38M | 164.30M | 5.94M |
| Total Debt | 2.51M | 2.77M | ||
| Net Cash (Debt) | 341.62M | 422.69M | 155.63M | 250.00K |
| Net Cash Per Share | 4.80 | 13.57 | 12,061.61 | 2.00 |
| Filing Date Shares Outstanding | 80.17M | 80.03M | 319.61K | 124.73K |
| Total Common Shares Outstanding | 80.12M | 79.99M | 319.61K | 124.73K |
| Working Capital | 190.74M | 397.36M | 139.11M | -12.84M |
| Book Value Per Share | 4.03 | 5.14 | -558.92 | -927.16 |
| Tangible Book Value | 323.11M | 411.10M | -178.64M | -115.64M |
| Tangible Book Value Per Share | 4.03 | 5.14 | -558.92 | -927.16 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Net Income | -182.11M | -134.04M | -74.28M | -64.70M |
| Depreciation & Amortization | 752.00K | 610.00K | 208.00K | 92.00K |
| Loss (Gain) From Sale of Investments | -132.00K | -1.26M | -1.54M | |
| Stock-Based Compensation | 15.47M | 5.87M | 4.42M | 16.46M |
| Other Operating Activities | 7.78M | 8.49M | 564.00K | |
| Change in Accounts Payable | 5.03M | -1.84M | 2.50M | 267.00K |
| Change in Other Net Operating Assets | 1.94M | 8.27M | 13.10M | -4.20M |
| Operating Cash Flow | -151.28M | -113.89M | -55.03M | -52.08M |
| Capital Expenditures | -284.00K | -606.00K | -49.00K | -414.00K |
| Investment in Securities | -191.07M | 73.93M | -122.89M | |
| Other Investing Activities | 2.41M | -2.41M | ||
| Investing Cash Flow | -191.36M | 73.33M | -120.53M | -2.82M |
| Issuance of Common Stock | 373.95M | 373.50M | 1.11M | 3.62M |
| Other Financing Activities | -8.77M | -12.32M | ||
| Financing Cash Flow | 365.18M | 383.40M | 206.29M | 55.12M |
| Net Cash Flow | 22.55M | 342.84M | 30.73M | 225.00K |
| Free Cash Flow | -151.56M | -114.50M | -55.08M | -52.49M |
| Free Cash Flow Per Share | -2.13 | -3.68 | -4,268.47 | -420.87 |
| Levered Free Cash Flow | -89.98M | -74.19M | -42.53M | |
| Unlevered Free Cash Flow | -89.98M | -74.19M | -42.53M | |
| Change in Working Capital | 6.97M | 6.43M | 15.59M | -3.94M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Market Capitalization | 188.81M | 1.00B | 246.84M | |
| Enterprise Value | -152.81M | 536.06M | ||
| Last Close Price | 2.62 | 12.52 | 10.50 | |
| PB Ratio | 0.65 | 2.44 | 1.71 | |
| P/TBV Ratio | 0.61 | 2.44 | ||
| Debt / Equity Ratio | 0.01 | 0.01 | ||
| Net Debt / Equity Ratio | -1.06 | -1.03 | -1.07 | 0.02 |
| Net Debt / EBITDA Ratio | 1.72 | 2.90 | 1.93 | 0.00 |
| Net Debt / FCF Ratio | 2.25 | 3.69 | 2.83 | 0.01 |
| Quick Ratio | 4.38 | 12.15 | 7.95 | 0.12 |
| Current Ratio | 4.69 | 12.34 | 8.11 | 0.23 |
| Return on Equity (ROE) | -81.92% | -48.23% | -110.95% | |
| Return on Assets (ROA) | -47.11% | -29.75% | -59.37% | |
| Return on Capital Employed (ROCE) | -61.20% | -35.30% | -55.90% | 597.90% |
| Earnings Yield | -108.67% | -13.38% | -30.09% | |
| FCF Yield | -77.16% | -11.43% | -22.31% | |
| Buyback Yield / Dilution | -12,503.20% | -241,276.23% | 89.66% |